We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Switzerland’s Novartis is shuttering several of its research operations in Switzerland and China, eliminating 175 jobs, in an effort to centralize control of its drug discovery programs and curb costs. Read More
The UK’s price watchdog is recommending reimbursement for AstraZeneca’s Tagrisso as a second-line treatment for an aggressive form of lung cancer. Read More
Violations of quality control standards for finished pharmaceuticals led to an FDA warning letter for Mappel Industria, a Brazil-based company. Read More
Hebei Yuxing Bio-Engineering, a Chinese producer of active pharmaceutical ingredients, has significant cGMP and data integrity issues at its manufacturing plant, the FDA said in a warning letter. Read More
Cheng Fong Chemical received a warning letter from the FDA for dirty equipment, poorly maintained facilities and improper investigations into possibly tainted batches of active pharmaceutical ingredients. Read More
The EMA has recommended that three medicines manufactured by Pharmaceuticals International no longer be available in the EU due to possible cross-contamination. Read More
British drugmaker GlaxoSmithKline will pay $20 million to settle the U.S. Securities and Exchange Commission’s charges that the company bribed healthcare professionals to boost drug sales in China. Read More
Indian drugmaker Lupin is facing delays in expanding its presence in the U.S. market after an FDA inspection uncovered deficiencies at a company facility. Read More
The Indian government has revised its list of essential medicines, removing price caps on dozens of drugs in a number of therapeutic classes. Read More
The United Nations High-Level Panel on Access to Medicine is proposing that governments rely on compulsory licenses to improve patient access to medicines in a highly anticipated report that has been met with dismay from industry. Read More